 Neena Kanwar
Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Molecular Diagnostic Techniques | 4 | 2021 | 36 | 2.690 |
Why?
| | Cephalosporins | 5 | 2023 | 15 | 2.010 |
Why?
| | Nucleic Acid Amplification Techniques | 4 | 2020 | 13 | 1.710 |
Why?
| | Drug Resistance, Multiple, Bacterial | 4 | 2023 | 11 | 1.520 |
Why?
| | Real-Time Polymerase Chain Reaction | 4 | 2020 | 38 | 1.380 |
Why?
| | Feces | 7 | 2023 | 37 | 1.220 |
Why?
| | Enterobacteriaceae | 3 | 2023 | 7 | 1.190 |
Why?
| | Respiratory Tract Infections | 2 | 2018 | 75 | 1.070 |
Why?
| | Enterobacteriaceae Infections | 2 | 2023 | 10 | 1.070 |
Why?
| | Sensitivity and Specificity | 7 | 2021 | 145 | 1.020 |
Why?
| | Influenza, Human | 3 | 2020 | 57 | 1.010 |
Why?
| | Anti-Bacterial Agents | 5 | 2023 | 238 | 0.990 |
Why?
| | Dysentery, Bacillary | 1 | 2023 | 2 | 0.920 |
Why?
| | Shigella | 1 | 2023 | 2 | 0.920 |
Why?
| | Pseudomonas Infections | 1 | 2023 | 7 | 0.900 |
Why?
| | Cystic Fibrosis | 1 | 2023 | 18 | 0.890 |
Why?
| | Child | 11 | 2023 | 3146 | 0.850 |
Why?
| | Infant | 10 | 2021 | 1396 | 0.850 |
Why?
| | Respiratory Syncytial Virus Infections | 3 | 2019 | 41 | 0.830 |
Why?
| | Adolescent | 9 | 2021 | 2087 | 0.820 |
Why?
| | Gastroenteritis | 2 | 2019 | 24 | 0.810 |
Why?
| | Escherichia coli | 3 | 2023 | 27 | 0.810 |
Why?
| | Young Adult | 6 | 2021 | 652 | 0.790 |
Why?
| | Child, Preschool | 8 | 2021 | 1459 | 0.780 |
Why?
| | Humans | 14 | 2023 | 6599 | 0.770 |
Why?
| | beta-Lactamases | 3 | 2018 | 6 | 0.760 |
Why?
| | Point-of-Care Testing | 1 | 2020 | 7 | 0.740 |
Why?
| | Nasopharynx | 5 | 2021 | 25 | 0.730 |
Why?
| | Aged, 80 and over | 5 | 2021 | 150 | 0.730 |
Why?
| | Prospective Studies | 5 | 2021 | 508 | 0.730 |
Why?
| | Male | 8 | 2021 | 3197 | 0.710 |
Why?
| | Female | 8 | 2021 | 3436 | 0.700 |
Why?
| | Aged | 5 | 2021 | 375 | 0.690 |
Why?
| | Automation, Laboratory | 1 | 2019 | 4 | 0.690 |
Why?
| | Bacterial Infections | 2 | 2021 | 27 | 0.690 |
Why?
| | Streptococcus pyogenes | 1 | 2019 | 13 | 0.690 |
Why?
| | Streptococcal Infections | 1 | 2019 | 19 | 0.670 |
Why?
| | Polymerase Chain Reaction | 1 | 2019 | 82 | 0.670 |
Why?
| | Mycoplasma pneumoniae | 1 | 2018 | 12 | 0.660 |
Why?
| | Pneumonia, Mycoplasma | 1 | 2018 | 15 | 0.660 |
Why?
| | Caliciviridae Infections | 1 | 2018 | 4 | 0.650 |
Why?
| | Middle Aged | 5 | 2021 | 648 | 0.650 |
Why?
| | Norovirus | 1 | 2018 | 7 | 0.650 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2018 | 64 | 0.640 |
Why?
| | Chlortetracycline | 3 | 2014 | 3 | 0.640 |
Why?
| | Adult | 5 | 2021 | 1233 | 0.560 |
Why?
| | Microbial Sensitivity Tests | 3 | 2023 | 32 | 0.540 |
Why?
| | Antigens, Viral | 1 | 2015 | 7 | 0.530 |
Why?
| | Immunoassay | 1 | 2015 | 8 | 0.520 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2015 | 16 | 0.520 |
Why?
| | Influenza B virus | 3 | 2020 | 22 | 0.520 |
Why?
| | Influenza A virus | 3 | 2020 | 20 | 0.520 |
Why?
| | United States | 6 | 2019 | 646 | 0.510 |
Why?
| | Tetracycline Resistance | 1 | 2014 | 1 | 0.500 |
Why?
| | Metagenome | 1 | 2014 | 1 | 0.500 |
Why?
| | Bacteria | 1 | 2014 | 9 | 0.500 |
Why?
| | Antiporters | 1 | 2013 | 1 | 0.480 |
Why?
| | Bacterial Proteins | 1 | 2013 | 8 | 0.480 |
Why?
| | Infant, Newborn | 4 | 2020 | 790 | 0.440 |
Why?
| | Pharynx | 2 | 2019 | 7 | 0.340 |
Why?
| | Respiratory Syncytial Virus, Human | 2 | 2019 | 23 | 0.340 |
Why?
| | Cattle | 3 | 2014 | 24 | 0.270 |
Why?
| | Animals | 3 | 2014 | 563 | 0.240 |
Why?
| | Cattle Diseases | 2 | 2013 | 3 | 0.230 |
Why?
| | Escherichia coli Infections | 2 | 2013 | 17 | 0.230 |
Why?
| | Azithromycin | 1 | 2023 | 5 | 0.230 |
Why?
| | Penicillanic Acid | 1 | 2023 | 2 | 0.230 |
Why?
| | Pseudomonas aeruginosa | 1 | 2023 | 7 | 0.230 |
Why?
| | Disease Outbreaks | 1 | 2023 | 30 | 0.220 |
Why?
| | Viral Load | 1 | 2021 | 20 | 0.210 |
Why?
| | Time Factors | 2 | 2019 | 241 | 0.200 |
Why?
| | Urinary Tract Infections | 1 | 2021 | 17 | 0.200 |
Why?
| | Bacteremia | 1 | 2021 | 25 | 0.200 |
Why?
| | Early Diagnosis | 1 | 2020 | 33 | 0.180 |
Why?
| | RNA Viruses | 1 | 2019 | 3 | 0.180 |
Why?
| | Rotavirus Vaccines | 1 | 2019 | 13 | 0.180 |
Why?
| | Cephalosporin Resistance | 1 | 2018 | 4 | 0.170 |
Why?
| | Carrier State | 1 | 2018 | 5 | 0.170 |
Why?
| | False Negative Reactions | 1 | 2018 | 10 | 0.160 |
Why?
| | Diagnostic Tests, Routine | 1 | 2018 | 17 | 0.160 |
Why?
| | Intestines | 1 | 2018 | 26 | 0.160 |
Why?
| | Genotype | 1 | 2018 | 395 | 0.150 |
Why?
| | Specimen Handling | 1 | 2015 | 18 | 0.130 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2014 | 7 | 0.130 |
Why?
| | Retrospective Studies | 2 | 2019 | 1251 | 0.060 |
Why?
| | Fever | 1 | 2021 | 26 | 0.050 |
Why?
| | Immunoenzyme Techniques | 1 | 2019 | 9 | 0.050 |
Why?
| | Age Distribution | 1 | 2019 | 31 | 0.050 |
Why?
| | Genotyping Techniques | 1 | 2019 | 21 | 0.050 |
Why?
| | Emergency Service, Hospital | 1 | 2021 | 129 | 0.050 |
Why?
| | Acute Disease | 1 | 2019 | 71 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2019 | 202 | 0.040 |
Why?
| | Prevalence | 1 | 2018 | 145 | 0.040 |
Why?
| | Risk Factors | 1 | 2018 | 460 | 0.040 |
Why?
| | Hospitalization | 1 | 2018 | 192 | 0.040 |
Why?
| | Plasmids | 1 | 2012 | 4 | 0.030 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|